Shares of Exact Sciences (EXAS) and Guardant Health (GH) are moving higher after privately held Freenome announced topline results from PREEMPT CRC, a clinical study to validate the company’s blood-based test for the early detection of colorectal cancer among average-risk adults. In a prespecified analysis, the Freenome blood test for colorectal cancer screening demonstrated 79.2% sensitivity in detecting colorectal cancer with 91.5% specificity for non-advanced colorectal neoplasia. The test also showed 12.5% sensitivity in detecting advanced adenomas. Shares of Exact Sciences (EXAS) are up 8% to $76.22 in early trading while Guardant Health is up 2% to $20.63. Both companies also offer blood-based cancer tests.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences’ Oncoguard Esophagus test shows efficacy in published study
- 5 Best Healthcare Stocks to Buy in March 2024, According to Analysts
- EXACT Sciences call volume above normal and directionally bullish
- Exact Sciences added to ‘Tactical Outperform’ list at Evercore ISI
- Exact Sciences says Cologuard Plus test results published in NEJM
